Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report)'s share price was down 7.5% during mid-day trading on Tuesday . The company traded as low as $14.93 and last traded at $14.95. Approximately 205,629 shares changed hands during trading, an increase of 310% from the average daily volume of 50,104 shares. The stock had previously closed at $16.16.
Neoleukin Therapeutics Price Performance
The firm has a market capitalization of $180.35 million, a price-to-earnings ratio of -6.17 and a beta of 1.11. The business's fifty day simple moving average is $17.41 and its 200 day simple moving average is $17.06.
About Neoleukin Therapeutics
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Stories
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
